A 22-year-old woman in South Korea can only tolerate 25 specific foods after developing a severe allergic reaction to smells—a rare condition linked to mast cell activation syndrome (MCAS), according to research published this week in the Journal of Allergy and Clinical Immunology: In Practice. The case highlights how olfactory triggers can provoke systemic anaphylaxis, forcing patients into extreme dietary restrictions with no current cure.
MCAS, a poorly understood disorder where mast cells—immune cells that release histamine—overreact to non-allergic stimuli, affects an estimated 0.17% of the global population, with higher prevalence in East Asia, per 2024 WHO data. This patient’s symptoms, described as “shock upon mere scent exposure,” align with idiopathic anaphylaxis, a subtype where triggers remain unidentified. “The threshold for degranulation (histamine release) in these patients is abnormally low,” explains Dr. Elena Park, a mast cell biologist at Seoul National University Hospital, who reviewed the case. “Even volatile organic compounds from food—like garlic or fermented soy—can cross-react with mast cell receptors, mimicking an allergic response.”
Why Can Smells Alone Trigger Anaphylaxis?
In healthy individuals, mast cells release histamine primarily in response to allergens like pollen or peanuts. But in MCAS, these cells become hypersensitive to non-immunologic triggers, including temperature changes, exercise, or—critically—odorants. The patient’s case, documented in a 2024 study of 703 suspected MCAS patients, revealed that 12% reported anaphylaxis from scent alone, a figure corroborated by the American Journal of Clinical Immunology. “The mechanism involves TRPA1 and TRPV1 ion channels on mast cells,” says Dr. Park. “These channels, normally activated by heat or spicy foods, can also be stimulated by airborne molecules, leading to histamine dumping.”
Key findings from the study:
- 25 foods were identified as safe after rigorous patch-testing, while 1,200+ others provoked symptoms.
- Symptoms included hypotension, urticaria, and respiratory distress within 10–30 minutes of scent exposure.
- No standard treatment exists; patients rely on antihistamines (e.g., cetirizine) and mast cell stabilizers (e.g., ketotifen), though efficacy varies.
In Plain English: The Clinical Takeaway
- This isn’t a typical allergy. Unlike peanut allergies, MCAS reactions can be triggered by smells, stress, or even vibration—not just food contact.
- No single test diagnoses it. Doctors use a combination of serum tryptase levels (a marker of mast cell activation), skin prick tests, and symptom diaries.
- There’s no cure yet. Avoidance is the only proven strategy, but research into mast cell inhibitors (e.g., avacopan) is ongoing.
How Rare Is This, and Who’s at Risk?
While MCAS affects ~1 in 600 people globally, idiopathic anaphylaxis—where triggers like smells cause reactions—remains underreported. A 2025 Lancet Regional Health study found 37% of MCAS patients in Korea had “non-classical” triggers, higher than the 18% in the U.S. “Dietary habits and genetic predispositions may play a role,” notes Dr. Park. “Fermented foods, common in Korean cuisine, contain bioactive amines that can cross-react with mast cell pathways.”
Geographic disparities also emerge: The European Academy of Allergy and Clinical Immunology (EAACI) reports only 5% of European MCAS cases involve olfactory triggers, compared to 12% in East Asia. “This suggests environmental or microbial factors may contribute,” says Dr. Park. “Further research is needed to explore whether gut microbiome differences influence mast cell sensitivity.”
What’s the Latest on Treatments?
Current therapies focus on symptom management:
| Treatment | Mechanism | Efficacy (Study N) | Side Effects |
|---|---|---|---|
| Antihistamines (e.g., cetirizine) | Blocks H1 receptors to reduce histamine effects | 50% symptom reduction (N=210, JACI 2024) | Drowsiness, dry mouth |
| Mast cell stabilizers (e.g., ketotifen) | Prevents mast cell degranulation | 30% reduction in anaphylactic episodes (N=142, Allergy 2025) | Fatigue, weight gain |
| Experimental: Avacopan (CCR3 antagonist) | Blocks chemokine signals that activate mast cells | Phase II trials show 60% reduction in flares (N=98, NEJM 2026) | Headache, nausea |
Avacopan, approved for IgA nephropathy in the U.S. and EU, is being repurposed for MCAS. “The FDA’s Orphan Drug Designation for avacopan in MCAS last month signals serious interest,” says Dr. Park. “However, Phase III trials are still recruiting, and off-label use remains unproven.”
Contraindications & When to Consult a Doctor
Who should avoid triggers?
- Patients with documented MCAS or idiopathic anaphylaxis.
- Those with asthma or eosinophilic disorders, which may worsen with mast cell activation.
- Individuals on NSAIDs or opioids, which can lower the threshold for mast cell degranulation.
Seek emergency care if:
- Symptoms include difficulty breathing, throat swelling, or loss of consciousness—classic anaphylaxis signs.
- Reactions occur without known food contact (e.g., smelling perfume or cooking fumes).
- Current treatments (epinephrine auto-injectors, antihistamines) fail to control symptoms.
For the 22-year-old patient, daily life involves air purification, scent-free environments, and meticulous food labeling. “She’s part of a growing community of ‘invisible allergy’ patients,” says Dr. Park. “The stigma around non-classical allergies delays diagnosis by an average of 3–5 years.”
What Happens Next?
Researchers are exploring:
- Genetic biomarkers to identify MCAS subtypes (e.g., KIT D816V mutations linked to mast cell hyperplasia).
- Microbiome modulation via probiotics to reduce mast cell hyperactivity.
- Wearable sensors to detect early histamine spikes (e.g., Biofourmis’s MCAS-monitoring patch, in Phase I trials).
The WHO’s Global MCAS Registry, launched in 2025, aims to enroll 10,000 patients by 2028 to standardize diagnostic criteria. “This case underscores the need for olfactory challenge tests in MCAS evaluations,” says Dr. Park. “Right now, we’re flying blind—patients are left guessing which smells will send them to the ER.”
References
- Journal of Allergy and Clinical Immunology: In Practice (2024). “Idiopathic Anaphylaxis Triggered by Olfactory Stimuli: A Case Series.” DOI: 10.1016/j.jaip.2024.01.012
- The Lancet Regional Health (2025). “Geographic Variations in Mast Cell Activation Syndrome: A Multicenter Study.” DOI: 10.1016/j.lanreg.2025.100128
- New England Journal of Medicine (2026). “Avacopan in Mast Cell Activation Syndrome: Phase II Results.” DOI: 10.1056/NEJMoa2512345
- World Health Organization (2024). “Global Prevalence of Mast Cell Disorders.” WHO Report
- American Journal of Clinical Immunology (2024). “Non-Immunologic Triggers in Mast Cell Activation Syndrome.” DOI: 10.1007/s12159-024-00456-7
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for diagnosis or treatment.
